Summit Therapeutics SMMT Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Teradyne, Inc.TER

$148.37M+30.4%

SS&C TechnologiesSSNC

$172.8M-0.7%

Starwood Property TrustSTWD

$308.2M-38.0%

IQVIAIQV

$95M-26.9%

eBayEBAY

$2.01B-22.3%

Prudential FinancialPRU

$6.92B-20.6%

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?: Summit Therapeutics (SMMT) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $492.22M in Q1 2026.
How has Summit Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?: Summit Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 228.6% year-over-year, from $149.79M to $492.22M.